X4 Pharmaceuticals is progressing its Phase 3 4WARD trial for mavorixafor, an oral treatment for primary chronic neutropenia (PCN), aiming to complete enrollment by Q4 2026. The company plans a Phase 2b 4STEPS trial in Q1 2027 to test reducing G-CSF doses with mavorixafor. Topline data from both trials are expected in Q1 2028, with potential FDA approval by late 2028 or early 2029. This therapy addresses a significant unmet need in PCN, a rare blood disorder with limited treatment options, and targets an estimated U.S. patient population of 15,000 to 30,000.
X4 Pharmaceuticals' clinical progress in primary chronic neutropenia provides context for health sector activity on Pluang. For readers following health stocks, 106 of 150 US health-sector stocks rose while 44 fell. Notable movers as of Oct 30, 2026 03:11 WIB include HLN at USD 8.58 with 0% Sell / 100% Buy order activity, CTXR at USD 0.60 with 100% Sell / 0% Buy, and WGS at USD 71.25 with 0% Sell / 100% Buy.
iHerb Holdings appointed Jordan Sweetnam, eBay's Chief Commercial Officer, as an independent director to its board. Sweetnam brings extensive experience in global eCommerce, having held senior roles at eBay and Walmart, and will support iHerb's expan...
SAP, a global enterprise software leader, will merge its North Texas operations into a new office in Addison, Texas, relocating about 1,000 employees from Plano and Allen. The new Spectrum Center location will house business operations, software deve...
Ipsos has appointed Mitch Barns as Chairman and CEO for the Americas region, effective November 2, 2026. Barns brings extensive leadership experience from his previous roles as Global CEO of Nielsen and CEO of The Opus Group, positioning him to drive...
Microsoft reported a strong Q1 with 19% year-over-year revenue growth, driven by robust AI demand and accelerating Azure cloud services. Despite a slight softness in gross margins, operating margins expanded, reflecting efficient cost management. The...
Pinterest reported third-quarter earnings of 46 cents per share and revenue of $1.17 billion, missing analyst expectations. The company also issued a revenue forecast for the current quarter that was lower than anticipated. This guidance led to a sha...
